Immune Thrombocytopenia Market share,Size, Statistics, And Regional Forecast To 2030
Immune
Thrombocytopenia Market Overview
Immune
thrombocytopenia market Share is a disorder that
refers to improper blood-clotting and its rising prevalence suggests that a
tentative 5.78% CAGR is quite possible for the global immune
thrombocytopenia market during the forecast period (2020-2027) and a
scaling of USD 2,300
Mn seems achievable. The disease causes a
drop in platelet count which ends in bruising and bleeding. It can occur in
both adults and children. The disease can get triggered by other diseases such
as autoimmune diseases, medications, chronic infections, pregnancy and certain
type of cancers.
Market Research Future (MRFR)
reveals that the Immune Thrombocytopenia Market can expect much
better positioning owing to the growing demand for drugs and therapeutics for
ITP. At the same time, countries are focusing much on research and development
and the investment in the sector has increased considerably. Treatment
facilities have also surged in numbers bolstering the growth of the immune
thrombocytopenia market.
The risk of immune thrombocytopenia is higher in people
having antiphospholipid syndrome, lupus, and rheumatoid arthritis. Immune
thrombocytopenia can result in small reddish-purple dots which appear as a rash
or purple bruise. It may have no symptoms, but when it occurs it may include
excessively heavy menstrual flow, blood in stools/urine, excessive or easy
bruising, bleeding from nose or gums, and superficial bleeding in the skin
which appear as reddish-purple spots that are pinpoint-sized and appear as a
rash, generally on the lower legs.
Immune Thrombocytopenia Market Segmentation
MRFR’s segmental analysis of the
segmental analysis of the global ITP market is based on type, treatment, and
end-user. The in-depth analysis would reveal the changing scenario of the
market with both volume-wise and value-wise data.
Based on the type, the immune
thrombocytopenia market Insights includes chronic immune thrombocytopenia and
acute immune thrombocytopenia. As per reports of 2017, the chronic immune
thrombocytopenia segment had around 85% of the global market share. The segment
is anticipating a CAGR of 5.94%to exceed a valuation of USD 2,036.9 Mn during
the forecast period.
Based on the treatment, the
immune thrombocytopenia market comprises intravenous immunoglobulins,
thrombopoietin receptor agonists, corticosteroids, and others. Records of 2017
suggests that, value-wise, the corticosteroids segmented had 40% of the
market under its wings share of the global ITP market. The segment is expected
to attain a CAGR of 5.57% over the review period. Its popularity grows with its
prolific use as steroid hormones in ITP therapies.
Based on the end-user, the immune
thrombocytopenia market Trends consists research
& academic institutes, specialty centers, hospitals & clinics, and
others. The hospitals & clinic segment has around 38% market share and is
projected to witness a CAGR of 6.22% during the forecast period.
Regional Analysis:
Geographical analysis of the
global ITP market, as conducted by MRFR, includes the Americas, Europe, Asia
Pacific (APAC) and the Middle East & Africa (MEA).
With a market reach of over
43.3%, the Americas is the dominating region and it is going to helm the market
during the assessment period. The prevalence of the disease is growing higher
and along with it, options of developing better cure. These features have been
further backed by robust reimbursement policies. Such features have created
substantial scope for the market to expand.
Europe is holding the second
position. The market in Europe has similar features like that of the Americas
owing to which the growth in the coming years would be intense. Other factors
such as increasing funding in the research and development sector can be taken
into consideration while measuring market possibilities.
The APAC market is quite
promising. The rate of growing awareness is quite high and revamping healthcare
sectors in emerging economies are providing much scope for expansion. The
regional market has also emerged as lucrative option for foreign players which
is why its growth rate in the coming years would be astonishing.
Competitive Landscape:
Players profiled by MRFR for
their remarkable contribution in the immune thrombocytopenia
market Players are CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd.,
Dova Pharmaceuticals, Kyowa Hakko Kirin Co., Ltd., Jiangsu Hengrui
Pharmaceutical Co., Ltd., Novartis AG, Ligand Pharmaceuticals, Inc., Shire,
Rigel Pharmaceuticals, Inc., and Shionogi Inc.
The American Society of
Hematology published an article in 2019 where low-dose chidamide is said to
hold ability to restore immune tolerance in immune thrombocytopenia. It
performs by starting a modulation of natural Treg cells and CTLA4 gene
expression. The published article points at a potentiality of the drug in
countering ITP in clinics.
At Market Research Future (MRFR), we enable our customers
to unravel the complexity of various industries through our Cooked Research
Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research
and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and
Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment